Dermatology’s growing focus on skin longevity demands clear definitions, validated outcomes, and rigorous evidence beyond anti-aging claims.
|Articles|August 1, 2004
FDA approves Botox for hyperhidrosis tx
Irvine, Calif. - Sweat has a new enemy. Botox (botulinum toxin type A), developed by Allergan, has been approved by the U.S. Food and Drug Administration (FDA) to treat hyperhidrosis.
Advertisement
Advertisement
Related to this article
Castor oil has become a popular social media remedy for thicker, longer hair, but evidence supporting its ability to stimulate hair growth remains limited.
Can “Botox in a bottle” really rival injectable neuromodulators? We examine the evidence behind topical peptide serums and Argireline.
Advertisement
Advertisement
Trending on Dermatology Times
1
AAD, HS Foundation Issue First Joint Hidradenitis Suppurativa Guidelines
2
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
3
Nonsteroidal Topicals Guide Special-Site Psoriasis Treatment Decisions
4
Fall Clinical 2026: The Data and Expert Advice Shaping Dermatology Practice
5